Spots Global Cancer Trial Database for Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Official Title: Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
Study ID: NCT01371565
Interventions
Study Description
Brief Summary: This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
University of Michigan Medical Center, Ann Arbor, Michigan, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
The Ohio State University, Division of Endocrinology Diabetes and Metabolism, Columbus, Ohio, United States
Contact Details
Name: Coleman Gross, M.D.
Affiliation: Corcept Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
